RSRonald M. Salomon

Ronald M. Salomon

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ronald M. Salomon has a total of 189 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Subthalamic nucleus deep brain stimulation in early stage Parkinson's disease

    by David Charles, Peter E. Konrad, Joseph S. Neimat, Anna L. Molinari, Michael G. Tramontana, Stuart G. Finder, Chandler E. Gill, Mark J. Bliton, Chris Kao, Fenna T. Phibbs, et al.


  • Fourier reflections.

    by Ronald M. Salomon

  • Oscillatory serotonin function in depression

    by Ronald M. Salomon, Ronald L. Cowan

    Oscillations in brain activities with periods of minutes to hours may be critical for normal mood behaviors. Ultradian (faster than circadian) rhythms of mood behaviors and associated central nervous system activities are altered in depression. Recent data suggest that ultradian rhythms in serotonin (5HT) function also change in depression. In two separate studies, 5HT metabolites in cerebrospinal fluid (CSF) were measured every 10 min for 24 h before and after chronic antidepressant treatment. Antidepressant treatments were associated with enhanced ultradian amplitudes of CSF metabolite levels. Another study used resting‐state functional magnetic resonance imaging (fMRI) to measure amplitudes of dorsal raphé activation cycles following sham or active dietary depletions of the 5HT precursor (tryptophan). During depletion, amplitudes of dorsal raphé activation cycles increased with rapid 6 s periods (about 0.18 Hz) while functional connectivity weakened between dorsal raphé and thalamus at slower periods of 20 s (0.05 Hz). A third approach studied MDMA (ecstasy, 3,4‐methylenedioxy‐N‐methylamphetamine) users because of their chronically diminished 5HT function compared with non‐MDMA polysubstance users (Karageorgiou et al., 2009). Compared with a non‐MDMA using cohort, MDMA users showed diminished fMRI intra‐regional coherence in motor regions along with altered functional connectivity, again suggesting effects of altered 5HT oscillatory function. These data support a hypothesis that qualities of ultradian oscillations in 5HT function may critically influence moods and behaviors. Dysfunctional 5HT rhythms in depression may be a common endpoint and biomarker for depression, linking dysfunction of slow brain network oscillators to 5HT mechanisms affected by commonly available treatments. 5HT oscillatory dysfunction may define illness subtypes and predict responses to serotonergic agents. Further studies of 5HT oscillations in depression are indicated.Synapse 67:801–820, 2013.


  • Increased oxidative stress in patients with depression and its relationship to treatment

    by Cecilia P. Chung, Dennis Schmidt, Charles Michael Stein, Jason D. Morrow, Ronald M. Salomon


  • Open Access

    Human ecstasy (MDMA) polydrug users have altered brain activation during semantic processing.

    by Tristan J. Watkins, Vidya Raj, Junghee Lee, Mary S. Dietrich, Aize Cao, Jennifer U. Blackford, Ronald M. Salomon, Sohee Park, Margaret M. Benningfield, Christina R. Di Iorio, et al.


  • Evidence for Chronically Altered Serotonin Function in the Cerebral Cortex of Female 3,4-Methylenedioxymethamphetamine Polydrug Users

    by Christina R Di Iorio, Tristan J Watkins, Mary S Dietrich, Aize Cao, Jennifer U Blackford, Baxter Rogers, Mohammed S Ansari, Ronald M Baldwin, Rui Li, Robert M Kessler, et al.

    MDMA (3,4-methylenedioxymethamphetamine, also popularly known as "ecstasy") is a popular recreational drug that produces loss of serotonin axons in animal models. Whether MDMA produces chronic reductions in serotonin signaling in humans remains controversial. To determine whether MDMA use is associated with chronic reductions in serotonin signaling in the cerebral cortex of women as reflected by increased serotonin(2A) receptor levels. Cross-sectional case-control study comparing serotonin(2A) receptor levels in abstinent female MDMA polydrug users with those in women who did not use MDMA (within-group design assessing the association of lifetime MDMA use and serotonin(2A) receptors). Case participants were abstinent from MDMA use for at least 90 days as verified by analysis of hair samples. The serotonin(2A) receptor levels in the cerebral cortex were determined using serotonin(2A)-specific positron emission tomography with radioligand fluorine 18-labeled setoperone as the tracer. Academic medical center research laboratory. A total of 14 female MDMA users and 10 women who did not use MDMA (controls). The main exclusion criteria were nondrug-related DSM-IV Axis I psychiatric disorders and general medical illness. Cortical serotonin(2A) receptor nondisplaceable binding potential (serotonin(2A)BP(ND)). MDMA users had increased serotonin(2A)BP(ND) in occipital-parietal (19.7%), temporal (20.5%), occipitotemporal-parietal (18.3%), frontal (16.6%), and frontoparietal (18.5%) regions (corrected P < .05). Lifetime MDMA use was positively associated with serotonin(2A)BP(ND) in frontoparietal (β = 0.665; P = .007), occipitotemporal (β = 0.798; P = .002), frontolimbic (β = 0.634; P = .02), and frontal (β = 0.691; P = .008) regions. In contrast, there were no regions in which MDMA use was inversely associated with receptor levels. There were no statistically significant effects of the duration of MDMA abstinence on serotonin(2A)BP(ND). The recreational use of MDMA is associated with long-lasting increases in serotonin(2A) receptor density. Serotonin(2A) receptor levels correlate positively with lifetime MDMA use and do not decrease with abstinence. These results suggest that MDMA use produces chronic serotonin neurotoxicity in humans. Given the broad role of serotonin in human brain function, the possibility for therapeutic MDMA use, and the widespread recreational popularity of this drug, these results have critical public health implications.


  • Deep brain stimulation in early Parkinson’s disease: Enrollment experience from a pilot trial

    by P.D. Charles, R.M. Dolhun, C.E. Gill, T.L. Davis, M.J. Bliton, M.G. Tramontana, R.M. Salomon, L. Wang, P. Hedera, F.T. Phibbs, et al.


  • Pilot Study Assessing the Feasibility of Applying Bilateral Subthalamic Nucleus Deep Brain Stimulation in Very Early Stage Parkinson's Disease: Study Design and Rationale

    by David Charles, Christopher Tolleson, Thomas L. Davis, Chandler E. Gill, Anna L. Molinari, Mark J. Bliton, Michael G. Tramontana, Ronald M. Salomon, Chris Kao, Lily Wang, et al.

    Background: Deep brain stimulation provides significant symptomatic benefit for people with advanced Parkinson's disease whose symptoms are no longer adequately controlled with medication. Preliminary evidence suggests that subthalamic nucleus stimulation may also be efficacious in early Parkinson's disease, and results of animal studies suggest that it may spare dopaminergic neurons in the substantia nigra. Objective: We report the methodology and design of a novel Phase I clinical trial testing the safety and tolerability of deep brain stimulation in early Parkinson's disease and discuss previous failed attempts at neuroprotection. Methods: We recently conducted a prospective, randomized, parallel-group, single-blind pilot clinical trial of deep brain stimulation in early Parkinson's disease. Subjects were randomized to receive either optimal drug therapy or deep brain stimulation plus optimal drug therapy. Follow-up visits occurred every six months for a period of two years and included week-long therapy washouts. Results: Thirty subjects with Hoehn & Yahr Stage II idiopathic Parkinson's disease were enrolled over a period of 32 months. Twenty-nine subjects completed all follow-up visits; one patient in the optimal drug therapy group withdrew from the study after baseline. Baseline characteristics for all thirty patients were not significantly different. Conclusions: This study demonstrates that it is possible to recruit and retain subjects in a clinical trial testing deep brain stimulation in early Parkinson's disease. The results of this trial will be used to support the design of a Phase III, multicenter trial investigating the efficacy of deep brain stimulation in early Parkinson's disease.


  • MDMA (Ecstasy) association with impaired fMRI BOLD thalamic coherence and functional connectivity

    by Ronald M. Salomon, John Karageorgiou, Mary S. Dietrich, Jessica Y. McLellan, Evonne J. Charboneau, Jennifer U. Blackford, Ronald L. Cowan


  • Human Ecstasy Use is Associated with Increased Cortical Excitability: An fMRI Study

    by Amy L Bauernfeind, Mary S Dietrich, Jennifer U Blackford, Evonne J Charboneau, James G Lillevig, Christopher J Cannistraci, Neil D Woodward, Aize Cao, Tristan Watkins, Christina R Di Iorio, et al.

    The serotonergic neurotoxin, 3,4-methylenedioxymethamphetamine (MDMA/Ecstasy), is a highly popular recreational drug. Human recreational MDMA users have neurocognitive and neuropsychiatric impairments, and human neuroimaging data are consistent with animal reports of serotonin neurotoxicity. However, functional neuroimaging studies have not found consistent effects of MDMA on brain neurophysiology in human users. Several lines of evidence suggest that studying MDMA effects in visual system might reveal the general cortical and subcortical neurophysiological consequences of MDMA use. We used 3 T functional magnetic resonance imaging during visual stimulation to compare visual system lateral geniculate nucleus (LGN) and Brodmann Area (BA) 17 and BA 18 activation in 20 long abstinent (479.95±580.65 days) MDMA users and 20 non-MDMA user controls. Lifetime quantity of MDMA use was strongly positively correlated with blood oxygenation level-dependent (BOLD) signal intensity in bilateral LGN (rs=0.59; p=0.007), BA 17 (rs=0.50; p=0.027), and BA 18 (rs=0.48; p=0.031), and with the spatial extent of activation in BA 17 (rs=0.059; p=0.007) and BA 18 (rs=0.55; p=0.013). There were no between-group differences in brain activation in any region, but the heaviest MDMA users showed a significantly greater spatial extent of activation than controls in BA 17 (p=0.031) and BA 18 (p=0.049). These results suggest that human recreational MDMA use may be associated with a long-lasting increase in cortical excitability, possibly through loss of serotonin input to cortical and subcortical regions. When considered in the context of previous results, cortical hyper-excitability may be a biomarker for MDMA-induced serotonin neurotoxicity.